LabPulse.com staff writersMergers & AcquisitionsLabcorp buys Invitae portfolio for $239MLabcorp was the winning bidder in the court-supervised auction of Invitae's assets, obtaining substantially all of the San Francisco-based company's business for $239 million in cash consideration with other noncash consideration.April 26, 2024Financial ResultsBristol Myers Squibb to reduce workforce in restructuring planAs part of a restructuring plan intended to cut $1.5 billion in costs, Bristol Myers Squibb plans to cut about 6% of its workforce, according to the firm.April 25, 2024ValidationImmunovia announces positive results for next-gen pancreatic cancer testDiagnostics company Immunovia announced positive results for the newest generation of its pancreatic cancer test from a model-development study, announcing that the test achieved both its primary and secondary endpoints.April 25, 2024CollaborationVertex to pay $25M upfront to scale cell manufacturing technologyAs part of the deal, Vertex was also willing to pay up to $215 million in milestones achieved in connection with the development of a scaled-up process for fully differentiated islet cells.April 25, 2024LawsuitU.K. Patents Court rules Bio-Techne patents invalid in infringement lawsuitThe Patents Court of the High Court of England and Wales has ruled that two patents owned by Bio-Techne are invalid, rejecting a patent infringement lawsuit filed by Bio-Techne/ACD in the U.K. against Molecular Instruments.April 24, 2024Alzheimer'sQuest adds new biomarker test to Alzheimer's portfolioQuest Diagnostics has launched a new blood biomarker test as part of its AD-Detect portfolio of blood tests for Alzheimer's disease risk assessment.April 23, 2024LawsuitBio-Techne files EU patent infringement suit against Molecular InstrumentsLife sciences company Bio-Techne has filed a lawsuit against Molecular Instruments in the pan-European Unified Patent Court, alleging patent infringement of its RNAscope in situ hybridization technology.April 23, 2024CollaborationIpsen, Skyhawk to collaborate on drug discovery for rare neurological disordersBiopharmaceutical company Ipsen and clinical-stage biopharmaceutical firm Skyhawk have signed an exclusive collaboration to discover and develop small-molecule therapeutics targeting RNA to treat rare neurological disorders.April 22, 2024Point-of-Care TestingScout secures CARB-X grant to advance diagnostic test developmentScout, formerly Uh Oh Labs, will advance its point-of-care (POC) diagnostic test for sexually transmitted infections (STIs) with a new $1 million accelerator grant.April 22, 2024Research and DevelopmentFujifilm Diosynth Biotechnologies confirms layoffsFujifilm Diosynth Biotechnologies confirmed a restructure that will result in the layoff of 240 employees.April 19, 2024Page 1 of 340Next PageTop StoriesFDA ClearancePillar Biosciences gets FDA approval for NGS solid tumor profiling testPillar Biosciences has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its OncoReveal CDx pan-cancer next-generation sequencing (NGS) test for general solid tumor profiling.ValidationImmunovia announces positive results for next-gen pancreatic cancer testCollaborationVertex to pay $25M upfront to scale cell manufacturing technologyMergers & AcquisitionsLabcorp buys Invitae portfolio for $239MSponsor ContentVisit our Molecular Diagnostics Community
